Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance.
DDR1
MAPK inhibitors
drug resistance
melanoma
therapeutic target
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
03
2020
accepted:
04
08
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
Melanoma is a highly malignant skin cancer with high propensity to metastasize and develop drug resistance, making it a difficult cancer to treat. Current therapies targeting BRAF (V600) mutations are initially effective, but eventually tumors overcome drug sensitivity and reoccur. This process is accomplished in part by reactivating alternate signaling networks that reinstate melanoma proliferative and survival capacity, mostly through reprogramming of receptor tyrosine kinase (RTK) signaling. Evidence indicates that the discoidin domain receptors (DDRs), a set of RTKs that signal in response to collagen, are part of the kinome network that confer drug resistance. We previously reported that DDR1 is expressed in melanomas, where it can promote tumor malignancy in mouse models of melanoma, and thus, DDR1 could be a promising target to overcome drug resistance. In this review, we summarize the current knowledge on DDRs in melanoma and their implication for therapy, with emphasis in resistance to MAPK inhibitors.
Identifiants
pubmed: 33014862
doi: 10.3389/fonc.2020.01748
pmc: PMC7516126
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1748Informations de copyright
Copyright © 2020 Reger de Moura, Prunotto, Sohail, Battistella, Jouenne, Marbach, Lebbé, Fridman and Mourah.
Références
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Cell Tissue Res. 2010 Jan;339(1):247-57
pubmed: 19693541
Cancer Discov. 2017 Nov;7(11):1248-1265
pubmed: 28864476
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Oncogene. 2013 Mar 7;32(10):1207-15
pubmed: 22562245
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7786-E7794
pubmed: 30061414
Nat Med. 2017 Aug;23(8):929-937
pubmed: 28714990
Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118473
pubmed: 30954568
Cell Adh Migr. 2018;12(4):363-377
pubmed: 29701112
ACS Chem Biol. 2013 Oct 18;8(10):2145-50
pubmed: 23899692
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
J Cell Biol. 2006 Nov 20;175(4):563-9
pubmed: 17101694
Mol Cell. 1997 Dec;1(1):25-34
pubmed: 9659900
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Pigment Cell Melanoma Res. 2019 Sep;32(5):697-707
pubmed: 31271515
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Cancer Cell. 2015 Jan 12;27(1):85-96
pubmed: 25500121
Cancer Metastasis Rev. 2012 Jun;31(1-2):295-321
pubmed: 22366781
Life Sci Alliance. 2019 Feb 13;2(1):
pubmed: 30760555
Mol Cell. 1997 Dec;1(1):13-23
pubmed: 9659899
Cancers (Basel). 2019 Sep 25;11(10):
pubmed: 31557826
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Nat Cell Biol. 2013 Jun;15(6):677-87
pubmed: 23644467
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Curr Opin Oncol. 2012 Mar;24(2):150-4
pubmed: 22316627
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Oncol Lett. 2018 Mar;15(3):3403-3408
pubmed: 29467865
Matrix Biol. 2006 Aug;25(6):355-64
pubmed: 16806867
Clin Cancer Res. 2019 Jun 1;25(11):3239-3246
pubmed: 30824584
J Mol Histol. 2004 Mar;35(3):309-18
pubmed: 15339050
Mol Cell Biol. 2001 Apr;21(8):2906-17
pubmed: 11283268
J Clin Invest. 2013 May;123(5):2155-68
pubmed: 23543055
Mol Biol Cell. 2011 Apr;22(7):940-53
pubmed: 21289093
J Cell Physiol. 2005 Apr;203(1):295-304
pubmed: 15468059
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Cell Adh Migr. 2018;12(4):315-323
pubmed: 30187813
Front Pharmacol. 2016 Mar 14;7:55
pubmed: 27014069
J Biol Chem. 2013 Mar 15;288(11):7430-7437
pubmed: 23335507
Matrix Biol. 2011 May;30(4):243-7
pubmed: 21477649
Curr Opin Oncol. 2010 May;22(3):178-83
pubmed: 20401974
Nature. 2012 Jul 26;487(7408):505-9
pubmed: 22763448
Cell. 2016 Jun 30;166(1):47-62
pubmed: 27368100
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Int Rev Cell Mol Biol. 2014;310:39-87
pubmed: 24725424
J Cell Commun Signal. 2018 Mar;12(1):113-118
pubmed: 29110248
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Eur J Cancer. 2015 Dec;51(18):2792-9
pubmed: 26608120
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103